Ispm Labs, LLC

Ispm Labs, LLC was paid $7.94M by Medicaid between Jan 2018 and Mar 2022, across 106 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 39% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Georgia

Rank by total paid#7 of 66

Median peer was paid$178K

This provider vs. median45×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	29,488	$1.11M
2019	67,116	$1.07M
2020	146,320	$2.85M
2021	116,110	$2.63M
2022	8,374	$272K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	39%	75,149	28,376	$3.12M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	8.8%	9,636	5,599	$701K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	8.3%	5,597	4,962	$662K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	6.9%	9,359	6,137	$548K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	5.8%	41,902	15,540	$457K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	4.2%	1,708	1,099	$336K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	3.9%	11,968	7,064	$309K
87150		2.1%	2,412	2,075	$165K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	1.9%	7,678	4,013	$149K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	2,241	1,339	$70K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	1,677	902	$68K
81226		<1%	1,366	1,114	$67K

94 more codes

81408		<1%	136	$53K
87640		<1%	9,239	$52K
87486		<1%	6,603	$51K
81225		<1%	1,367	$44K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	4,502	$42K
87500		<1%	3,742	$42K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	1,714	$38K
87581		<1%	6,603	$30K
87541		<1%	6,591	$29K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	2,559	$28K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	2,559	$28K
87653		<1%	2,595	$27K
87641		<1%	2,407	$26K
81231		<1%	1,063	$24K
81230		<1%	1,062	$24K
80355		<1%	4,293	$24K
80366		<1%	3,729	$24K
81328		<1%	1,057	$23K
87481		<1%	2,595	$23K
81227		<1%	1,049	$22K
81401		<1%	1,080	$22K
81378		<1%	155	$22K
80337		<1%	1,216	$21K
80346		<1%	4,140	$18K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	791	$18K
87532		<1%	3,959	$18K
81241		<1%	1,062	$17K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	2,036	$17K
83992		<1%	4,084	$16K
81479	Unlisted molecular pathology procedure	<1%	1,885	$16K
80348		<1%	4,396	$16K
80360		<1%	4,276	$15K
80359		<1%	4,287	$15K
81240		<1%	1,066	$14K
80358		<1%	4,113	$13K
80349		<1%	4,072	$12K
80373		<1%	4,018	$12K
80372		<1%	4,296	$12K
80361		<1%	4,269	$12K
80367		<1%	3,717	$12K
80338		<1%	657	$12K
80363		<1%	4,097	$11K
80333		<1%	621	$11K
81355		<1%	1,046	$11K
80329		<1%	640	$11K
80345		<1%	4,067	$11K
81291		<1%	1,225	$10K
80365		<1%	4,379	$10K
80354		<1%	4,392	$10K
80356		<1%	4,331	$10K
81405		<1%	121	$9K
81407		<1%	60	$9K
81404		<1%	60	$9K
87631		<1%	4,884	$9K
80336		<1%	2,674	$9K
81201		<1%	60	$9K
80377		<1%	617	$8K
80323		<1%	944	$8K
80353		<1%	4,128	$8K
80332		<1%	2,618	$8K
81406		<1%	115	$8K
80344		<1%	657	$8K
81292		<1%	60	$8K
80321		<1%	2,583	$7K
80370		<1%	3,288	$7K
81317		<1%	60	$7K
87529		<1%	1,552	$7K
81321		<1%	60	$7K
80324		<1%	3,403	$6K
80368		<1%	825	$6K
81298		<1%	60	$6K
80369		<1%	674	$4K
81247		<1%	154	$4K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	1,554	$4K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	128	$4K
80334		<1%	187	$3K
81295		<1%	60	$3K
81307		<1%	43	$3K
80162		<1%	158	$2K
87496		<1%	5,226	$2K
80340		<1%	158	$2K
80325		<1%	643	$2K
80343		<1%	158	$2K
87511		<1%	841	$2K
80362		<1%	600	$2K
87498		<1%	4,857	$2K
81283		<1%	154	$2K
87563		<1%	328	$1K
81403		<1%	17	$124.34
82570		<1%	787	$123.02
80371		<1%	13	$103.14
81003		<1%	783	$60.92
80364		<1%	12	$60.00
84311		<1%	513	$35.64

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMALONEY, ANDREW (OWNER)